Ionis Pharmaceuticals vs TG Therapeutics
Ionis Pharmaceuticals is the larger business, with $944m of revenue in fiscal 2025 against $616m for TG Therapeutics (1.5 times as much). TG Therapeutics grew faster (87.3% against 33.8%). TG Therapeutics kept more of each dollar of sales as profit: a net margin of 72.6% against -40.4%. TG Therapeutics carries less debt relative to equity (37.9% against 370.6%).
| Latest fiscal year | Ionis PharmaceuticalsIONS, 2025 | TG TherapeuticsTGTX, 2025 |
|---|---|---|
| Revenue | $944m | $616m |
| Revenue growth | 33.8% | 87.3% |
| Net income | −$381m | $447m |
| Operating margin | -40.4% | 20.0% |
| Net margin | -40.4% | 72.6% |
| Return on equity | -70.8% | 102.8% |
| Free cash flow | −$320m | −$25.0m |
| Cash | $372m | $79.1m |
| Total debt | $1.81bn | $246m |
| Debt to equity | 370.6% | 37.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $91.2m |
| Employees | 1,402 | 399 |
| Market value | $6.75bn | $9.32bn |
| Price vs our value range | — | — |
| Moat score | 35 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 2 buys, 116 sales | 0 buys, 2 sales |